Arcus Biosciences, Inc.

RCUSSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1724521

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$37.0M	$38.0M	$383.0M	$78.0M	$15.0M
Research and Development Expense	$340.0M	$288.0M	$257.0M	$159.0M	$78.5M
Operating Expenses	$457.0M	$392.0M	$329.0M	$202.0M	$103.7M
Operating Income (Loss)	-$340.0M	-$280.0M	$54.0M	-$124.0M	-$88.7M
Nonoperating Income (Expense)	$39.0M	$14.0M	$1.0M	$1.0M	$4.0M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$301.0M	-$266.0M	$55.0M	-$123.0M	-$84.7M
Income Tax Expense (Benefit)	$6.0M	$1.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.1B	$1.1B	$1.3B	$1.6B	$772.3M
Assets, Current	$1.0B	$831.0M	$1.1B	$1.3B	$735.8M
Cash and Cash Equivalents, at Carrying Value	$150.0M	$127.0M	$206.0M	$148.0M	$173.4M
Liabilities	—	—	—	—	$270.0M
Liabilities, Current	$226.0M	$184.0M	$193.0M	$166.0M	$121.7M
Long-term Debt	$48.0M	$0.00	—	—	—
Accounts Payable, Current	$18.0M	$17.0M	$20.0M	$10.0M	$15.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$306.0M	$438.0M	-$256.0M	$111.0M	-$73.5M
Net Cash Provided by (Used in) Investing Activities	$194.0M	-$413.0M	-$4.0M	-$434.0M	$59.2M
Net Cash Provided by (Used in) Financing Activities	$33.0M	$33.0M	$237.0M	$439.0M	$1.1M
Payments to Acquire Property, Plant, and Equipment	$24.0M	$6.0M	$26.0M	$3.0M	$1.9M
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)